These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28303028)

  • 1. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
    Yang K; Chen Y; To KK; Wang F; Li D; Chen L; Fu L
    Exp Mol Med; 2017 Mar; 49(3):e303. PubMed ID: 28303028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
    Mi YJ; Liang YJ; Huang HB; Zhao HY; Wu CP; Wang F; Tao LY; Zhang CZ; Dai CL; Tiwari AK; Ma XX; To KK; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2010 Oct; 70(20):7981-91. PubMed ID: 20876799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
    Zhao XQ; Xie JD; Chen XG; Sim HM; Zhang X; Liang YJ; Singh S; Talele TT; Sun Y; Ambudkar SV; Chen ZS; Fu LW
    Mol Pharmacol; 2012 Jul; 82(1):47-58. PubMed ID: 22491935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
    Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
    Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo.
    Zhang DM; Shu C; Chen JJ; Sodani K; Wang J; Bhatnagar J; Lan P; Ruan ZX; Xiao ZJ; Ambudkar SV; Chen WM; Chen ZS; Ye WC
    Mol Pharm; 2012 Nov; 9(11):3147-59. PubMed ID: 23046348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
    Liu KJ; He JH; Su XD; Sim HM; Xie JD; Chen XG; Wang F; Liang YJ; Singh S; Sodani K; Talele TT; Ambudkar SV; Chen ZS; Wu HY; Fu LW
    Int J Cancer; 2013 Jan; 132(1):224-35. PubMed ID: 22623106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.